stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Total debt
AstraZeneca PLC's total debt at the end of fiscal 2025 was $27.8B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $31.4B. Over the past ten years it has ranged from $15.1B (fiscal 2015) to $29.8B (fiscal 2021); the current reading is higher than 73% of that period. AstraZeneca PLC ranks 10th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $27.8B | (3.55%) |
| FY2024 | $28.8B | 4.91% |
| FY2023 | $27.5B | (2.78%) |
| FY2022 | $28.3B | (5.08%) |
| FY2021 | $29.8B | 51.25% |
| FY2020 | $19.7B | 12.23% |
| FY2019 | $17.6B | (8.17%) |
| FY2018 | $19.1B | 7.33% |
| FY2017 | $17.8B | 5.94% |
| FY2016 | $16.8B | 11.66% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $31.4B | 6.52% |
| Jun 2026 | $29.5B | (7.93%) |
| Mar 2026 | $32.0B | 15.14% |
| Dec 2025 | $27.8B | (9.90%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. compare | $80.9B |
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| MRK Merck & Co., Inc. compare | $51.1B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| AZN AstraZeneca PLC | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement